Back to today’s briefing

Story perspectives

Wegovy Surge Makes Novo Nordisk Europe's Top Firm

7/29/2025

38 9

Summary

Story summary

Novo Nordisk's Wegovy weight loss drug is gaining traction after a US ban on knockoffs, propelling the company to become Europe's most valuable firm. Despite a shaky market outlook, analysts argue that its long-term growth potential is overlooked. However, prescription data is still lacking, as it doesn't account for direct-to-consumer sales through NovoCare.

1 of 1

Story summary

Novo Nordisk's Wegovy weight loss drug is gaining traction after a US ban on knockoffs, propelling the company to become Europe's most valuable firm. Despite a shaky market outlook, analysts argue that its long-term growth potential is overlooked. However, prescription data is still lacking, as it doesn't account for direct-to-consumer sales through NovoCare.